Shares of Landauer, Inc. (NYSE:LDR) have earned an average broker rating score of 4.00 (Sell) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation and one has issued a hold recommendation on the company.

Brokers have set a twelve-month consensus price objective of $44.50 for the company, according to Zacks. Zacks has also given Landauer an industry rank of 191 out of 265 based on the ratings given to related companies.

A number of analysts recently commented on LDR shares. Zacks Investment Research cut Landauer from a “hold” rating to a “sell” rating in a research report on Wednesday, May 17th. BidaskClub cut Landauer from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in Landauer by 20.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 249,548 shares of the scientific and technical instruments company’s stock valued at $12,003,000 after buying an additional 42,190 shares during the period. Vanguard Group Inc. boosted its stake in Landauer by 4.2% in the first quarter. Vanguard Group Inc. now owns 848,773 shares of the scientific and technical instruments company’s stock valued at $41,377,000 after buying an additional 34,013 shares during the period. Renaissance Technologies LLC boosted its stake in Landauer by 11.6% in the first quarter. Renaissance Technologies LLC now owns 274,600 shares of the scientific and technical instruments company’s stock valued at $13,387,000 after buying an additional 28,600 shares during the period. Marshall Wace North America L.P. acquired a new stake in Landauer during the second quarter valued at approximately $1,198,000. Finally, Bernzott Capital Advisors boosted its stake in Landauer by 5.0% in the second quarter. Bernzott Capital Advisors now owns 447,156 shares of the scientific and technical instruments company’s stock valued at $23,386,000 after buying an additional 21,250 shares during the period. Institutional investors own 81.80% of the company’s stock.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/landauer-inc-ldr-given-consensus-rating-of-by-analysts/1477196.html.

Landauer (LDR) opened at 61.70 on Friday. The firm has a market cap of $594.66 million, a PE ratio of 31.95 and a beta of 1.30. Landauer has a 12 month low of $41.00 and a 12 month high of $62.85. The stock’s 50 day moving average is $55.10 and its 200 day moving average is $52.07.

Landauer (NYSE:LDR) last posted its quarterly earnings data on Tuesday, August 8th. The scientific and technical instruments company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.18. The firm had revenue of $39.89 million during the quarter. Landauer had a return on equity of 80.03% and a net margin of 12.09%. On average, equities analysts forecast that Landauer will post $1.79 earnings per share for the current year.

About Landauer

Landauer, Inc is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products.

Get a free copy of the Zacks research report on Landauer (LDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Landauer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.